Biomerieux Sa · EURONEXT:BIM
Biomerieux Sa — H1 2026 Earnings Presentation
35 slides from Biomerieux Sa's earnings presentation, Jul 28, 2026
Slide 1: H1 2026 Results & 2026 outlook
H1 2026 Results & 2026 outlook Pierre BOULUD CHIEF EXECUTIVE OFFICER Guillaume BOUHOURS CHIEF FINANCIAL OFFICER July 28th 2026 PIONEERING DIAGNOSTICS
Slide 2: Agenda
Agenda 01 H1 2026 – Key Highlights 02 Q2 2026 – Business Highlights 03 H1 2026 - Financial Performance 04 2026 Outlook 04 2027 & 2028 Ambitions B I O M É R I E U X
Slide 3: Disclaimers
Disclaimers This presentation contains information, assumptions and estimates that were used by the Company to determine its objectives on a reasonable basis. They are subject to change or modification due to economic, financial, medical and competitive uncertainties in markets addressed by bioMérie
Slide 4: H1 2026 Key Highlights
H1 2026 KEY HIGHLIGHTS PIONEERING DIAGNOSTICS
Slide 5: H1 2026 – Key Highlights
H1 2026 – Key Highlights CONTRIBUTIVE FREE SALES EBIT CASHFLOW €1,965m €313m €299m +0.2%1 15.9% +76% vs H1 2025 of sales Cash positive ▪ Sales growth accelerated in Q2 (+5%1, +7.3% excl. respiratory panel sales) from Q1 26 (-3.9%) which was impacted by low respiratory epidemiology ▪ CEBIT declined b
Slide 6: H1 2026 – On-going implementation of the GO.28 initiatives
H1 2026 – On-going implementation of the GO.28 initiatives HEADCOUNTS REINFORCING OUR ON TRACK TO REACH EVOLUTION CONTROL STRONG EMPLOYEES' LEADERSHIP IN THE CSR AMBITION HIGHPLEX MOLECULAR ENGAGEMENT BIOFIRE® : GI.1.1 panels FDA SG&A EFFICIENCY submission MARKETING, FINANCE & -31% CUSTOMER SERVICE:
Slide 7: Q2 2026 Business Highlights
Q2 2026 BUSINESS HIGHLIGHTS PIONEERING DIAGNOSTICS
Slide 8: Q2 26: solid +5% sales growth
Q2 26: solid +5%* sales growth Growth drivers: +8.5%* INDUSTRIAL BIOFIRE® non-respiratory SPOTFIRE® MICROBIOLOGY APPLICATIONS +7%* +38%* +6.5%* +9%* ▪ Installed base expansion ▪+40%* in reagents’ sales ▪Strong dynamic in Blood ▪ Reagents sales up double ▪ On-going cross selling ▪7,200 instruments (J
Slide 9: H1 2026 Financial Performance
H1 2026 Financial Performance PIONEERING DIAGNOSTICS
Slide 10: H1 2026 sales: stable evolution despite a challenging respiratory season
H1 2026 sales: stable evolution despite a challenging respiratory season Sales growth % are expressed at constant exchange rates SPOTFIRE +22% ▪ 7,200 instruments installed MICROBIOLOGY +4% at the end of June 2026 ▪ +5% excl. China ▪ Reagents sales up +35% ▪ Strong dynamic in BACT/ALERT ® reagents s
Slide 11: H1 2026 sales by geography
H1 2026 sales by geography EMEA +2%* NORAM -1%* €647m 33% of sales €888m Sales growth driven by Molecular (BIOFIRE® non-RP 45% of sales panels), Industrial Sales growth in Industrial Applications, and Applications, microbiology Microbiology and BIOFIRE® non-RP panels ASPAC -3%* LATAM €287m +11%* 15%
Slide 12: HY 2026 P&L: reported CEBIT down -5% like-for-like
HY 2026 P&L: reported CEBIT2 down -5% like-for-like1 H1 % H1 % % % In €m sales sales Change Change LFL(1) 2026 2025 Net sales 1,965 2,044 - 3.9% + 0.2% Gross profit 1,098 55.9% 1,167 57.1% - 5.9% -1.1% SG&A -544 27.7% -569 27.8% - 4.3% - 2.1% R&D -257 13.1% -249 12.2% + 3.2% + 5.0% CEBIT (2) 313 15.
Slide 13: H1 2026 P&L: CEBIT to EPS
H1 2026 P&L: CEBIT to EPS H1 % H1 % % change % In €m sales sales Change LFL(1) 2026 2025 as reported CEBIT 313 15.9% 372 18.2% - 15.7 % -4.9% Amortization of acquired intangible assets & related expenses -14 -163 Operating income before non recurring items 299 15.2% 209 10.2% + 43.3% Net financial e
Slide 14: Strong free cash flow: up +€130m vs H1 2025
STRONG FREE CASH FLOW: up +€130m vs H1 2025 • Receivables (+€63m): efficient cash collection, Millions € June 2026 June 2025 especially in the US, combined with sales effect EBITDA (1) 440 495 • Inventories (+€7m) driven by raw material inventory optimization in the US Working capital requirement 19
Slide 15: 2026 Outlook
2026 Outlook PIONEERING DIAGNOSTICS
Slide 16: 2026 Full Year Guidance
2026 FULL YEAR GUIDANCE GUIDANCE ASSUMPTIONS +3% to +5% • Microbiology +3%* to +5%* • BIOFIRE® non RP ~+8%* Organic evolution • SPOTFIRE® ~+35%* to +45% SALES • Industrial Applications ~+7%* to +9%* Q1 26 Actual:-3.9% • Immunoassays -5%* to 0%* Q2 26 Actual:+5.0% • BIOFIRE® respiratory panels ~ -8%*
Slide 17: 2027 & 2028 ambitions
2027 & 2028 ambitions PIONEERING DIAGNOSTICS
Slide 18: Continue to execute on GO.28 pillars with adjusted financial targets
Continue to execute on GO.28 pillars with adjusted financial targets reflecting the geopolitical and macroeconomic environment ▪ Aiming at +3% to +6% annual sales growth at constant exchange for Growth rates and scope in 2027 and 2028 ▪ Focus on GO.28 growth drivers ▪ Continue the implementation of
Slide 19: 2027 & 2028 ambitions
2027 & 2028 ambitions PIONEERING DIAGNOSTICS
Slide 20: GO for Growth – 2027 & 2028 sales growth ambition
GO for GROWTH – 2027 & 2028 SALES GROWTH AMBITION BIOFIRE® Industrial BIOFIRE® RP SPOTFIRE® Microbiology Immunoassays Non-RP Applications +4%1 to ~-5%1 ~+25%1 +3%1 to ~-5%1 +7%1 to 8%1 at stable to +5%1 to 0% 1 +9%1 respiratory +40%1 season Aiming at +3% to +6% 1 annual organic sales growth in 2027
Slide 21: BIOFIRE non-respiratory panels: leveraging the superior solution
BIOFIRE® non-respiratory panels: leveraging the superior solution to address untapped geographies and segments Best in Class Solution • Fastest Time to Result: ~1 hour (non-RP) • Largest menu in the market Meningitis Blood Culture • Fireworks unique software allowing real-time epidemiology monitorin
Slide 22: SPOTFIRE sales growth: continue to gain market shares
SPOTFIRE® sales growth: continue to gain market shares leveraging the unique features of the solution & the menu expansion BEST IN CLASS SOLUTION • Uniquely positioned with 100% of assays CLIA Waived to truly address the PoC market • Fastest Time To Result : ~15mns Respiratory Respiratory / Sore Thr
Slide 23: Microbiology sales: leveraging AMR market growth and innovation
MICROBIOLOGY sales: leveraging AMR market growth and innovation continued upgrades AMR /AMS trend** *** • > 1m deaths per year as a result of AMR • Expected to reach ~10m by 2050 • Blood culture practice normalization post bottles supply challenges MARKET LEADER • Fully integrated offer from ID to A
Slide 24: Industrial applications to grow +7/9% annually to 2028
Industrial applications to grow +7/9% annually1 to 2028 by bringing innovation in dynamic segments Strong underlying macro trends • Growing and ageing population • Worldwide increase in regulatory pressure • Digitalization and automation of testing methods Innovation • Molecular: GENE-UP®, Mycoplasm
Slide 25: BIOFIRE RP & Immunoassays: maximizing value from established franchises
BIOFIRE® RP & IMMUNOASSAYS: maximizing value from established franchises ~-5%* ~-5%* to flat* annual sales evolution in 2027 & 2028 annual sales evolution in 2027 & 2028 at stable respiratory season OPPORTUNITIES CAPTURE GROWTH IN DYNAMIC MARKETS • Growth potential from OUS expansion of the • India,
Slide 26: 2027 & 2028 ambitions
2027 & 2028 ambitions PIONEERING DIAGNOSTICS
Slide 27: 50+ initiatives to strengthen the operating leverage
CEBIT to grow organically higher than organic sales growth 50+ initiatives to strengthen the operating leverage COGS G&A / R&D S&M • Automation • Process automation • Customer service efficiency • Internalization • New operating models • Launch excellence program • Procurement • Focused investments
Slide 28: 2027 & 2028 ambitions
2027 & 2028 ambitions PIONEERING DIAGNOSTICS
Slide 29: Continue to strengthen team members' engagement
CONTINUE TO STRENGTHEN TEAM MEMBERS’ ENGAGEMENT CLEAR ASSIGNMENT OF REINFORCED DELEGATIONS DECISION-MAKING ROLES DEPLOYMENT OF CORE PROCESSES SIMPLIFICATION 5 CORE BEHAVIORS Be in the 1st quartile for employees’ engagement across healthcare industries B I O M É R I E U X
Slide 30: 2027 & 2028 ambitions
2027 & 2028 ambitions PIONEERING DIAGNOSTICS
Slide 31: 2028 CSR Roadmap
2028 CSR ROADMAP ACCESSIBILITY NET ZERO CO2e BY 2050 SAFETY ETHICS PHILANTHROPY % of patient Improve Total net income results Reduction in GHG Recordable Incident Ethics score of attributable to the supporting AMS emissions & Occupational parent company Ecovadis in low & lower-middle Illness Rate an
Slide 32: Key Take Aways
Key Take Aways PIONEERING DIAGNOSTICS
Slide 33: Key Take Aways
Key Take Aways Solid Q2 2026 performance: +5% organic sales growth Confirmation of the 2026 guidance: • Sales expected to grow between +3% to +5% organic • CEBIT expected to grow between +0% and +10% organic • FX impact: ~-€40m to -€50m Adjustement of 2027 and 2028 financial perspectives: • Organic
Slide 34: Pioneering Diagnostics
PIONEERING DIAGNOSTICS B I O M É R I E U X
Slide 35: Main CSR KPIs follow-up
MAIN CSR KPIS FOLLOW-UP AS OF END OF JUNE 2026 ACCESSIBILITY NET ZERO CO2e BY 2050 SAFETY ETHICS PHILANTHROPY +45% patient In absolute value vs. 2023: results SCOPES 1&2: -31% TR2IR: 0.52 N/A supporting AMS 2025: 0.8 N/A SCOPE 3: N/A 2025: 79/100 in low & lower-middle Mental Health Index: N/A 2025: